Loading clinical trials...
Loading clinical trials...
QUILT-205: Long-Term Follow-Up of Subjects in QUILT-2.005 Phase 1b Trial of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)
The purpose of this clinical trial is to obtain long-term follow-up information and status of bladder cancer for patients who received study treatment in the QUILT-2.005 study.
All 9 subjects that completed QUILT-2.005 phase 1b are planned to be enrolled in this study. Thus, the maximum enrollment for this study is 9 subjects. All enrolled subjects will be followed every 12 months for life, or until withdrawal of consent, or if the Sponsor closes the study.
Age
All ages
Sex
ALL
Healthy Volunteers
No
Island Urology
Honolulu, Hawaii, United States
Start Date
August 17, 2023
Primary Completion Date
August 30, 2033
Completion Date
August 30, 2033
Last Updated
March 13, 2025
6
ACTUAL participants
N803 plus Bacillus Calmette-Guerin (BCG)
DRUG
Lead Sponsor
ImmunityBio, Inc.
NCT04452591
NCT06181266
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions